Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes

ConferenceKO-7246Positive

AI Analysis

Summary

Caspian Therapeutics unveiled KO-7246, a potential best-in-class menin inhibitor for diabetes, at EASD, demonstrating regeneration of functional β-cell mass and durable glycemic control in preclinical Type 1 and Type 2 diabetes models.

Importance:5/10

Sentiment:

0.60

menin inhibitordiabetesbeta-cell regenerationEASDType 1 diabetesType 2 diabetes

Related Companies

$MEHA $INTI

Read the original article

Published by GlobeNewswire Pharma on September 29, 2026 9:15 AM

Read Original